Skip to main content

Table 1 Baseline characteristics by gender

From: Gender difference in the impact of gynoid and android fat masses on the progression of hepatic steatosis in Japanese patients with type 2 diabetes

  Female (N = 116) Male (N = 178) P values
Age (years) 65 ± 9 65 ± 10 0.915
SBP (mmHg) 125 ± 15 129 ± 14 0.032
DBP (mmHg) 72 ± 14 77 ± 12 0.002
Body mass index (kg/m2) 24.5 ± 4.7 25.0 ± 4.2 0.314
Grip strength (kg) 18.7 ± 5.4 31.5 ± 8.2 < 0.001
Skeletal muscle index 5.9 ± 0.9 7.2 ± 1.1 < 0.001
Total fat mass (kg) 22.2 ± 8.6 21.1 ± 8.2 0.281
Total non-fat mass (kg) 33.8 ± 5.4 46.5 ± 7.1 < 0.001
Andoroid (kg) 2.0 ± 1.0 2.2 ± 1.1 0.104
Gynoid (kg) 3.3 ± 1.2 2.9 ± 1.3 0.004
Andoroid (%) 8.3 ± 1.9 9.8 ± 1.8 < 0.001
Gynoid (%) 15.0 ± 2.8 13.4 ± 1.4 < 0.001
Body fat (%) 38.8 ± 7.4 30.3 ± 6.8 < 0.001
VFA (cm2) 119 ± 61 150 ± 71 < 0.001
SFA (cm2) 192 ± 88 145 ± 86 < 0.001
Liver attenuation index 1.15 ± 0.31 1.10 ± 0.34 0.445
Duration of diabetes (years) 6 (5–7) 8 (6–9) 0.059
HbA1c (mmol/mol) 54 ± 12 57 ± 11 0.143
HbA1c (%) 6.9 ± 1.5 7.2 ± 1.4 0.143
Triglycerides (mmol/l) 1.58 (1.7–1.80) 1.74 (1.56–1.80) 0.275
HDL cholesterol (mmol/l) 1.65 ± 0.55 1.45 ± 0.40 < 0.001
LDL cholesterol (mmol/l) 3.16 ± 0.89 2.77 ± 0.72 0.012
AST (U/l) 29 (25–33) 28 (23–30) 0.605
ALT (U/l) 28 (23–32) 29 (26–33) 0.556
γ-GTP (U/l) 46 (36–57) 64 (54–74) 0.020
Uric acid (μmol/l) 284 (271–297) 337 (325–348) < 0.001
eGFR (ml/min/1.73 m2) 74.8 ± 23.3 72.9 ± 20.8 0.456
Log ACR (mg/g) 1.59 ± 0.59 1.52 ± 0.62 0.355
PDR (%) 8 5 0.217
History of CVD (%) 5 15 0012
C-reactive protein (mg/l) 0.19 (0.16–0.25) 0.21 (0.13–0.28) 0.716
Insulin (%) 26 24 0.801
Sulfonylureas (%) 11 16 0.263
Biguanides (%) 24 23 0.859
Alpha-GIs (%) 3 7 0.218
Glinides (%) 4 3 0.689
TZDs (%) 3 4 0.820
DPP4 inhibitors (%) 29 30 0.815
GLP1 receptor agonists (%) 1 2 0.366
SGLT2 inhibitors (%) 0 1 0.851
ARBs (%) 32 38 0.290
Calcium channel blockers (%) 32 34 0.750
Statins (%) 37 31 0.347
Anti-platelet agents (%) 8 17 0.023
  1. Abbreviations: ACR albumin-to-creatinine ratio, ALT alanine transaminase, ARBs angiotensin receptor blockers, AST aspartate transaminase, CVD cardioivascular disease, DBP diastolic blood pressure, DPP4 dipeptidyl peptidase 4, eGFR estimated glomerular filtration ratio, GIs glycosidase inhibitors, GLP1 glucagon-like peptide-1; GTP, glutamyl transpeptidase, HDL high-density lipoprotein, LDL low-density lipoprotein, PDR proliferative diabetic retinopathy, SBP systolic blood pressure, SFA subcutaneous fat area, SGLT2 sodium-glucose cotransporter 2, TZDs thiazolidinediones, VFA visceral fat area